cuda shuda ....haaa
huey & duey........2013 .........Concerned Shareholders' belief, based on years of experience in human health drug development, is that Urocidin is a high-risk program and it's reasonable to assume it will take years, possibly five years or longer, for it to get to the market in the U.S., which assumes a successful Phase III trial, something no one can predict. The cost before that time could easily be in the tens of millions of dollars. By the Company's own admission that number could be $40 million.